Introduction: Why USP 467 Residual Solvents Testing is Essential for Pharma Manufacturers
USP 467 Residual Solvents testing is an important requirement for pharmaceutical manufacturers to ensure drug safety, regulatory compliance, and product quality. The U.S. Pharmacopeia (USP) General Chapter <467> sets detailed guidelines for identifying and quantifying residual solvents that may remain in drug substances, excipients, or final products. If not properly controlled, these solvents can cause serious health risks for patients.
ResolveMass Laboratories Inc. is a trusted testing partner providing fully validated USP 467 residual solvents testing for U.S. and Canadian pharmaceutical and biopharma companies. Our advanced methods, regulatory alignment, and fast turnaround times make us the top choice for manufacturers seeking audit-ready, strong scientific solutions.
👉 Explore our complete Residual Solvent Testing Services
What Is USP 467 Residual Solvents Testing?
Understanding the USP <467> Framework
USP 467 Residual Solvents testing is the official procedure approved by the United States Pharmacopeia (USP) to identify and control organic volatile impurities (OVIs) that may remain in pharmaceutical products after manufacturing. These residual solvents can be harmful if not properly monitored, especially over long-term exposure. USP <467> provides clear guidance on how to test for these substances using standardized methods. It helps ensure product safety and regulatory compliance for both drug manufacturers and contract labs. The guideline also classifies solvents into three categories:
- Class 1: Solvents to be avoided due to toxicity or environmental concerns
- Class 2: Solvents to be limited due to inherent toxicity
- Class 3: Solvents with low toxic potential
Each class has defined limits and acceptable daily exposures (ADEs) for patients.
👉 Read more: Class 1, 2, and 3 Residual Solvents Explained
Why USP 467 Residual Solvents Testing Matters
- 🧪 Patient Safety: Prevents exposure to carcinogenic or toxic chemicals
- 🏛️ Regulatory Compliance: Required by FDA for IND, NDA, ANDA submissions
- 🌍 Global Acceptance: Aligns with ICH Q3C guidelines used worldwide
- 📋 Audit Readiness: Essential during GMP inspections and regulatory audits
At ResolveMass, we support pharmaceutical manufacturers in meeting the strict USP 467 residual solvents limits to ensure product safety and compliance. Our team uses advanced analytical techniques, such as headspace GC-FID, to accurately detect and quantify residual solvents. We also offer expert support throughout the testing process to help clients confidently meet regulatory requirements.
Types of Solvents Tested Under USP <467>
Class 1 Solvents (To Be Avoided)
These are solvents with known toxicity and no acceptable therapeutic use, meaning they should be avoided in drug products. Even small amounts can cause serious health risks, so their presence must be strictly controlled. Examples include:
- Benzene (Limit: 2 ppm)
- Carbon tetrachloride (Limit: 4 ppm)
- 1,2-Dichloroethane (Limit: 5 ppm)
Class 2 Solvents (To Be Limited)
These solvents are commonly used in pharmaceutical manufacturing, but due to their potential toxicity, their levels must be strictly restricted. They should not exceed the Permitted Daily Exposure (PDE) limits set by USP 467.
- Methanol (Limit: 3000 ppm)
- Acetonitrile (Limit: 410 ppm)
- Toluene (Limit: 890 ppm)
Class 3 Solvents (Low Toxic Potential)
These solvents are considered less toxic and are often used in pharmaceutical processes in small amounts. They are usually permitted up to 5000 ppm, as they cause minimal risk when used within acceptable limits. Examples include:
- Ethanol
- Acetone
- 2-Propanol
ResolveMass offers full-spectrum testing across Class 1, 2, and 3 solvents as defined by USP 467.
We use validated methods to ensure each sample meets the required residual solvent specifications. This helps manufacturers stay compliant while ensuring product safety and quality.
👉 Check our Class-Wise Testing Capabilities
How USP 467 Residual Solvents Testing is Performed
We follow a three-level testing strategy as recommended by the USP:
🔹 Procedure A: Initial Screening
Headspace Gas Chromatography with Flame Ionization Detection (HS-GC-FID) is a widely used technique to detect common residual solvents in pharmaceutical samples.
It works by analyzing the headspace above the sample without needing to inject the liquid directly. This method is sensitive, efficient, and ideal for general screening as required under USP 467.
🔹 Procedure B: Confirmatory Testing
Used when the results from Procedure A are unclear or show possible solvent presence near the limit. It is specifically designed to detect certain solvents that may not be easily identified in the initial screening. This step provides a more focused and accurate analysis for those specific residual solvents.
🔹 Procedure C: Class 1 Solvent Confirmation
Specially designed to detect low ppm levels of highly toxic solvents, this method ensures even trace amounts are accurately identified. At ResolveMass, our lab uses advanced GC-MS and HS-GC-FID systems that are fully validated for high sensitivity. These techniques allow us to go beyond basic USP 467 detection limits for greater precision and safety assurance.
👉 Learn about our validated testing methods
Real-Time Case Study: USP 467 Compliance in a U.S. Biotech Startup
Client: A U.S.-based biotech company launching its first peptide-based injectable drug.
Problem: During early validation, residual levels of acetonitrile (Class 2) went over the allowed 410 ppm, with readings around 660 ppm. In-house testing lacked sensitivity for low-ppm accuracy.
Solution: ResolveMass carried out USP 467 residual solvents testing using HS-GC with internal standard calibration. Validation confirmed acetonitrile levels at 660 ppm, leading to a change in the purification process.
Outcome:
- After reprocessing: Residual acetonitrile = 120 ppm (well below the limit)
- Documentation: Audit-ready CoA and method validation reports
- Turnaround: Within 72 hours
- Result: IND approved, batch released for Phase I trials
This case shows the importance of partnering with a lab experienced in USP 467 residual solvents compliance for early-phase drug development.
👉 Talk to our analytical team today
Sample Requirements and Turnaround Time
- Sample amount: 100–500 mg (solid) or 1–2 mL (liquid)
- Typical turnaround: 3–5 business days
- Rush analysis: Within 24–48 hours
All testing complies with FDA, USP <467>, and ICH Q3C standards.
👉 Submit a sample or request a quote
Benefits of Choosing ResolveMass for USP 467 Residual Solvents Testing
- ✅ Decades of pharma testing experience
- ✅ Expertise in ICH, USP, and FDA regulations
- ✅ Custom method development and validation
- ✅ Quick turnaround and competitive pricing
- ✅ Trusted by CDMOs, generics, and specialty pharma
👉 Explore our Testing Services
FAQs
USP 467 defines the testing steps and limits for residual solvents in pharmaceutical products. All manufacturers submitting to FDA must follow these rules.
Residual solvents are trace amounts of volatile organic compounds left behind during manufacturing. They must be controlled due to health risk concerns.
Class 1 are carcinogenic and should be avoided. Class 2 are toxic and must be limited. Class 3 are less toxic but still monitored.
Using Headspace Gas Chromatography (HS-GC), often with FID or MS detectors. Each solvent class may need a different analytical approach.
Yes. The FDA requires USP 467 residual solvents testing for all drug applications including ANDAs, NDAs, and INDs.
Usually 3–5 business days. Faster results can be delivered within 24–48 hours with rush service.
Yes. Full testing methods allow multi-solvent detection in a single run, saving both time and money.
You get a full Certificate of Analysis (CoA), method validation details, chromatograms, and a regulatory compliance statement.
Yes. We offer testing across all pharmaceutical matrices, ensuring USP 467 compliance for each component.
Simply fill out our contact form and our team will guide you on shipping, sample size, and labeling.
Conclusion: Be Audit-Ready with USP 467 Residual Solvents Testing by ResolveMass
USP 467 Residual Solvents testing is no longer just a best practice—it is a regulatory necessity. Whether you’re developing a new API, changing a drug formula, or scaling up production, following USP <467> ensures safety, efficacy, and global market access.
ResolveMass Laboratories Inc. is a trusted partner in this process, offering validated methods, strong scientific accuracy, and a team of analytical experts who understand the details of residual solvent testing.
👉 Speak with a testing specialist
Internal Resources for Further Reading
- 🔗 Residual Solvent Testing Services
- 🔗 Testing in Canada: Regulatory Insights
- 🔗 USP 467 Compliance in the U.S.
- 🔗 Class 1, 2, 3 Residual Solvents Blog
